BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BiO2 Medical, Inc. Raises $12 Million in Series C Funding


9/10/2012 7:04:43 AM

SAN ANTONIO, Sept. 7, 2012 /PRNewswire/ -- BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding. The company worked closely with BiO2 Medical's investment bankers, Pasadera Capital for this Series C round. This funding will allow BiO2 Medical to commercialize the Angel Catheter. Remeditex Ventures, LLC led the round along with BiO2 Medical's existing investors.

Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer said, "We are thrilled to have Remeditex join on with BiO2 Medical, as they bring a tremendous amount of experience to the company. We are all looking forward to a successful launch of the Angel Catheter which will provide a valuable tool for providing PE prophylaxis in critically ill patients."

"We are excited to be part of the highly qualified BiO2 Medical team. BiO2 has developed a promising product that addresses a significant unmet medical need," said John Creecy, Chief Executive Officer and Director of Remeditex Ventures. "We believe the company is poised to become an important innovator, addressing the needs of patients by substantially reducing the risks associated with pulmonary embolism."

BiO2 Medical's Angel Catheter, named after its inventor and BiO2 Medical's Chief Medical Officer, Dr. Luis F. Angel, is a central venous catheter and Inferior Vena Cava (IVC) filter combination device, intended to protect against potentially fatal Pulmonary Embolism (PE) in critically ill patients. The Angel Catheter will include a first of its kind prophylactic indication for IVC filter use. For more information regarding BiO2 Medical and the Angel Catheter, please visit www.bio2medical.com.

SOURCE BiO2 Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->